Loading
A phase 2 trial of Vorolanib and Atezolizumab in Extensive-stage small-cell lung cancer, run by Washington University School of Medicine, recorded as terminated on the registry.
Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer is a phase 2 interventional study registered as NCT04373369 by Washington University School of Medicine, with 11 participants recorded, started 2020-10-07 and due to reach its primary completion in 2022-08-18. Interventions recorded: Vorolanib, Atezolizumab. Conditions recorded: Extensive-stage Small Cell Lung Cancer.
Linked to the drug Vorolanib because the registry names it among its interventions and Extensive-stage small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
11 enrolled.
90% CI 8.9 to 49.8; Figures from the ClinicalTrials.gov results section (first posted 2023-06-02), not from a publication
Source90% CI 5.1 to 16.7; Figures from the ClinicalTrials.gov results section (first posted 2023-06-02), not from a publication
SourceShares Vorolanib and the tag pipeline.
Shares Vorolanib and the tag pipeline.
Shares Extensive-stage small-cell lung cancer and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Atezolizumab and the tag pipeline.
Shares Extensive-stage small-cell lung cancer and the tag pipeline.
Shares Atezolizumab and the tag pipeline.
Shares Atezolizumab and the tag pipeline.
Shares Atezolizumab and the tag pipeline.